FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965086744> ?p ?o ?g. }

• W1965086744 endingPage "274" @default.
• W1965086744 startingPage "268" @default.
• W1965086744 abstract "The use of an adenovirus transduced to express a prostate cancer antigen (PSA) as a vaccine for the treatment of prostate cancer has been shown to be active in the destruction of antigen-expressing prostate tumor cells in a pre-clinical model, using Balb/C or PSA transgenic mice. The destruction of PSA-secreting mouse prostate tumors was observed in Ad/PSA immunized mice in a prophylaxis study with 70% of the mice surviving long term tumor free. This successful immunotherapy was not observed in therapeutic studies in which tumors were established before vaccination and the development of anti-PSA immune response was not as easily generated in PSA transgenic mice. Immunization of conventional and transgenic animals was enhanced by incorporating a collagen matrix into the immunizing injection. Therefore the need to strengthen anti-PSA and anti-prostate cancer immunity was an obvious next step in developing a successful prostate cancer immunotherapy. Because the use of immunostimulatory CpG motifs was shown to enhance immune responses to a wide variety of antigens, our studies incorporated CpG into the Ad/PSA vaccine experimental plans. The results of the subsequent studies demonstrated a dichotomy where Ad/PSA plus CpG enhanced the in vivo destruction of PSA-secreting tumors and the survival of experimental animals, but revealed that the number and in vitro activities of antigen specific CD8+ T cells was decreased as compared to the values observed when the vaccine alone was used for immunization. The dichotomous observations were confirmed using another antigen system, OVA also incorporated into a replication defective adenovirus. Despite the reduction in antigen-specific CD8+ cells after vaccine plus CpG immunization the enhanced destruction of sc and systemic tumors was shown to be mediated entirely by CD8+ T cells. Finally, the reduction of the CD8+ T cells was the result of an observed decrease in the proliferation of the antigen specific cell population." @default.
• W1965086744 created "2016-06-24" @default.
• W1965086744 creator A5032781343 @default.
• W1965086744 creator A5086713976 @default.
• W1965086744 date "2009-03-01" @default.
• W1965086744 modified "2023-09-23" @default.
• W1965086744 title "CpG oligonucleotide as an adjuvant for the treatment of prostate cancer" @default.
• W1965086744 cites W1521418395 @default.
• W1965086744 cites W1584584037 @default.
• W1965086744 cites W1939858431 @default.
• W1965086744 cites W1964196894 @default.
• W1965086744 cites W1968735524 @default.
• W1965086744 cites W1969945114 @default.
• W1965086744 cites W1970133494 @default.
• W1965086744 cites W1970245838 @default.
• W1965086744 cites W1977663329 @default.
• W1965086744 cites W1979603317 @default.
• W1965086744 cites W1984363557 @default.
• W1965086744 cites W1987860197 @default.
• W1965086744 cites W1988331000 @default.
• W1965086744 cites W1988437817 @default.
• W1965086744 cites W1988608904 @default.
• W1965086744 cites W1991932325 @default.
• W1965086744 cites W1994466260 @default.
• W1965086744 cites W1999625461 @default.
• W1965086744 cites W2006219146 @default.
• W1965086744 cites W2010916432 @default.
• W1965086744 cites W2017064782 @default.
• W1965086744 cites W2024914696 @default.
• W1965086744 cites W2032947856 @default.
• W1965086744 cites W2037409113 @default.
• W1965086744 cites W2037416455 @default.
• W1965086744 cites W2041267131 @default.
• W1965086744 cites W2043103956 @default.
• W1965086744 cites W2046731425 @default.
• W1965086744 cites W2052692252 @default.
• W1965086744 cites W2058447401 @default.
• W1965086744 cites W2064291021 @default.
• W1965086744 cites W2066684818 @default.
• W1965086744 cites W2067910064 @default.
• W1965086744 cites W2068917085 @default.
• W1965086744 cites W2070046036 @default.
• W1965086744 cites W2071192671 @default.
• W1965086744 cites W2072492830 @default.
• W1965086744 cites W2073778314 @default.
• W1965086744 cites W2074566129 @default.
• W1965086744 cites W2078684250 @default.
• W1965086744 cites W2078700629 @default.
• W1965086744 cites W2083155294 @default.
• W1965086744 cites W2084953975 @default.
• W1965086744 cites W2085802461 @default.
• W1965086744 cites W2086190595 @default.
• W1965086744 cites W2087144130 @default.
• W1965086744 cites W2090176935 @default.
• W1965086744 cites W2092427263 @default.
• W1965086744 cites W2098574945 @default.
• W1965086744 cites W2101591679 @default.
• W1965086744 cites W2103080556 @default.
• W1965086744 cites W2112813954 @default.
• W1965086744 cites W2113510389 @default.
• W1965086744 cites W2114040719 @default.
• W1965086744 cites W2115459972 @default.
• W1965086744 cites W2115751426 @default.
• W1965086744 cites W2117884326 @default.
• W1965086744 cites W2119216117 @default.
• W1965086744 cites W2120575356 @default.
• W1965086744 cites W2123501358 @default.
• W1965086744 cites W2124999867 @default.
• W1965086744 cites W2130227816 @default.
• W1965086744 cites W2144350507 @default.
• W1965086744 cites W2149274368 @default.
• W1965086744 cites W2149421090 @default.
• W1965086744 cites W2149426298 @default.
• W1965086744 cites W2149484379 @default.
• W1965086744 cites W2149752186 @default.
• W1965086744 cites W2156983262 @default.
• W1965086744 cites W2160069559 @default.
• W1965086744 cites W2261691410 @default.
• W1965086744 cites W2278250224 @default.
• W1965086744 cites W2316240194 @default.
• W1965086744 cites W4235084121 @default.
• W1965086744 doi "https://doi.org/10.1016/j.addr.2008.12.005" @default.
• W1965086744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19166887" @default.
• W1965086744 hasPublicationYear "2009" @default.
• W1965086744 type Work @default.
• W1965086744 sameAs 1965086744 @default.
• W1965086744 citedByCount "23" @default.
• W1965086744 countsByYear W19650867442012 @default.
• W1965086744 countsByYear W19650867442013 @default.
• W1965086744 countsByYear W19650867442014 @default.
• W1965086744 countsByYear W19650867442015 @default.
• W1965086744 countsByYear W19650867442017 @default.
• W1965086744 countsByYear W19650867442018 @default.
• W1965086744 countsByYear W19650867442019 @default.
• W1965086744 countsByYear W19650867442022 @default.
• W1965086744 crossrefType "journal-article" @default.
• W1965086744 hasAuthorship W1965086744A5032781343 @default.
• W1965086744 hasAuthorship W1965086744A5086713976 @default.

• next